Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AbbVie’s Rova-T Sees Another Failure

AbbVie halted a Phase III trial evaluating rovalpituzumab tesirine as a second-line therapy for advanced small-cell lung cancer after an Independent Data Monitoring Committee called for the stoppage due to shorter overall survival in the Rova-T arm.

Read More »

Daiichi Sankyo denies AstraZeneca takeover bid

Japanese drugmaker Daiichi Sankyo denied that it received a takeover bid during 2016 from Britain’s AstraZeneca.

Read More »

Astellas Takes a $387 Million+ Loss as It Shuts Down SoCal’s Agensys

Astellas Pharma announced that the company is wrapping up its research operations with Santa Monica, Calif.-based Agenus.

Read More »

FDA Slaps Hold on IND for Vadastuximab Talirine

The U.S. FDA placed a hold on Seattle Genetics’ Investigational New Drug Application for vadastuximab talirine.

Read More »

Seattle Genetics Halts Phase III Leukemia Study

Seattle Genetics halted all clinical trials of its vadastuximab talirine due to higher incidents of death associated with the treatment for AML patients.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom